Enhancing immune response against brain tumors using specialized vesicles.
Boosting IL-12-induced anti-glioblastoma activity via immunotherapeutic extracellular vesicles.
This study is looking at a new way to help people with glioblastoma, a tough brain cancer, by using tiny particles to make a treatment called interleukin-12 work better, which could improve their chances after their cancer comes back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10993191 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for patients with glioblastoma, a type of aggressive brain cancer. The approach involves using extracellular vesicles to boost the effects of interleukin-12, a substance that can enhance the immune system's ability to fight tumors. By combining these elements, the research aims to develop a new strategy that could lead to better outcomes for patients whose cancer has returned after initial treatment. The project also emphasizes the professional development of the lead researcher, ensuring a strong foundation for future advancements in cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who have limited treatment options after initial therapies.
Not a fit: Patients with newly diagnosed glioblastoma who have not yet undergone treatment may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with recurrent glioblastoma, potentially extending survival and improving quality of life.
How similar studies have performed: Previous research has shown promising results with similar immunotherapeutic approaches in treating glioblastoma, indicating potential for success in this novel strategy.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Breyne, Koen — Massachusetts General Hospital
- Study coordinator: Breyne, Koen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.